

**From:** [Do, Yu](#)  
**To:** [dmyers@malvernconsultinggroup.com](mailto:dmyers@malvernconsultinggroup.com)  
**Subject:** Information Request: Response Due by Tuesday, July 05, 2016 - Original BLA, BL 125590/0, Immune Globulin Intravenous (Human), ADMA Biologics, Inc.  
**Date:** Tuesday, June 28, 2016 11:09:42 AM  
**Importance:** High

---

Dear Diane:

We are reviewing your original July 31, 2015, submission to BLA 125590/0 for Immune Globulin Intravenous (Human). We are providing the following comment and request additional information to continue our review:

1. Please submit the lot release protocol template revised in accordance with the following comment:

With reference to Table 5 Potency on page 3 of 5, please remove an entire row regarding the test for (b) (4).

The review of this submission is ongoing and issues may be added, expanded upon, or modified as we continue to review this submission. Please submit your response as an amendment to this file by July 05, 2016, referencing the date of this request. If you anticipate you will not be able to respond by this date, please contact the Agency immediately so a new response date can be identified.

If we determine that your response to this information request constitutes a major amendment, we will notify you in writing.

The action due date for this file is July 30, 2016.

Please acknowledge receipt of this request and contact me at (240) 402-8343 or [Yu.Do@fda.hhs.gov](mailto:Yu.Do@fda.hhs.gov) if you have any questions.

Sincerely,  
Yu Do, M.S.  
Regulatory Project Manager  
FDA/OMPT/CBER/OBRR/RPMS  
(240) 402-8343  
[yu.do@fda.hhs.gov](mailto:yu.do@fda.hhs.gov)

"THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender by e-mail or phone."